research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris [2016/11/14 13:03] schillil |
research:concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris [2020/04/29 21:09] crundle |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ======Characterization of Oral Antibiotics for Acne Treatment====== | + | =====Characterization of Oral Antibiotics for Acne Treatment====== |
| - | **Objective:** // | + | **Objective:** |
| - | We aim to characterize 1) the use of oral antibiotics for the treatment of acne in children and adolescents and 2)assess guideline compliance of current clinical practice around the world.// | + | Aim 1: Characterize the international distribution of oral antibiotic use for acne in the pediatric and young adult population ages 12 to 20. |
| + | Aim 2: Characterize the international distribution of oral antibiotic use for acne in the adult population ages 21 to 40. | ||
| - | **Rationale:** //Acne is a common and disabling medical problem, especially among adolescents.[1] Guidelines established by the American Academy of Dermatology (AAD) recommend to minimize the duration of systemic antibiotics for the management of acne ideally to 3-4 months and no longer than 6 months in order to decrease risk of resistance.[1] A recent systematic review demonstrated that over 50% of P acnes strains are reported as resistant in all major regions of the world.[2] In addition to promoting resistance, long-term oral antibiotic use has been associated with a number of adverse events including microbiome disruption and pharyngitis, and possible associations with inflammatory bowel disease and obesity.[3] Despite these adverse effects, oral antibiotics are often prescribed for acne for longer durations than acne guidelines recommend.[3] A large retrospective cohort study of teenagers in the UK revealed that 29% of antibiotic courses prescribed by general practitioners exceeded 6 months in duration.[3] OHDSI network evidence will identify areas of the globe most in need of improving guideline concordance.// | + | //**Rationale:** // |
| + | Acne is a common and disabling medical condition, particularly amongst adolescents and young adults.[1] According to the Global Burden of Disease Study 2016, acne is the most disabling skin condition worldwide, responsible for 0.28% of global burden from all diseases.[2] In addition to physical disfigurement, the profound psychosocial effects of acne have been recognized for over half a century.[3] Guidelines established by the American Academy of Dermatology recommend minimizing the duration of systemic antibiotics for the management of acne ideally to 3-4 months and no longer than 6 months in order to decrease risk of resistance.[1] A recent systematic review demonstrated that over 50% of P. acnes strains are reported as resistant in all major regions of the world.[4] In addition to promoting resistance, long-term oral antibiotic use has been associated with a number of adverse events including microbiome disruption and pharyngitis, as well as possible associations with inflammatory bowel disease and obesity.[5] Despite these adverse effects, oral antibiotics are often prescribed for acne for longer durations than acne guidelines recommend.[5] A large retrospective cohort study of teenagers in the UK revealed that 29% of antibiotic courses prescribed by general practitioners exceeded 6 months in duration.[5] A similar retrospective cohort study of teenagers and young adults in the US found that 18% of antibiotic courses exceeded 6 months.[6] Our study will investigate oral antibiotic use for acne over the last ten years across the globe in both pediatric/young adult and adult populations. OHDSI network evidence will identify areas of the globe most in need of improving guideline concordance//.// | ||
| - | **Project Lead(s):** //Stephanie Chapman, Renee Domozych, Jessica Mounessa, Jonathan Silverberg, David Barbieri, Robert P. Dellavalle, Lisa M. Schilling// | + | **Project Lead(s):** //Robert P. Dellavalle, Lisa M. Schilling// |
| - | **Full Draft Protocol:** {{research:acne:acne_abx_characterization_protocol.docx}} | + | **Coordinating Institution(s):** //University of Colorado School of Medicine// |
| + | **Additional Participants:** // //Chante Karimkhani: ck2525@caa.columbia.edu | ||
| + | Chandler Rundle: chandler.rundle@gmail.com | ||
| + | Megan Branda: MEGAN.BRANDA@cuanschutz.edu | ||
| + | John Barbieri: john.barbieri@uphs.upenn.edu | ||
| + | Chris Knoll: cknoll1@its.jnj.com | ||
| + | David Margolis: margo@mail.med.upenn.edu | ||
| + | Patrick Ryan: ryan@ohdsi.org | ||
| + | Martijn Schuemie: m.schuemie@erasmusmc.nl | ||
| + | Jonathan Silverberg: JonathanISilverberg@gmail.com | ||
| + | Dylan Ray: DYLAN.RAY@cuanschutz.edu | ||
| + | Sara Deakyne: Sara.DeakyneDavies@childrenscolorado.org | ||
| + | **Full Draft Protocol:** //Please provide any comments or suggestions.// | ||
| + | [[https://docs.google.com/document/d/1LnugUQrloOn-3cZJDdTpgVYEsynu7SBztFtjzjAuEDE/edit]] | ||
| + | **Initial Proposal Date:** //25 August 2016// | ||
| - | + | **Launch Date:** // // | |
| - | //Please provide any comments or suggestions.// | + | |
| - | ===== Forum Discussion Thread ===== | + | **Study Closure Date:** // // |
| - | [[http://forums.ohdsi.org/t/ohdsi-study-concordance-with-antibiotic-treatment-guidelines-for-acne/1703]]// | + | |
| + | **Forum Discussion Thread** | ||
| + | |||
| + | http://forums.ohdsi.org/t/ohdsi-study-concordance-with-antibiotic-treatment-guidelines-for-acne/1703 | ||
research/concordance_with_aad_guidelines_for_the_treatment_of_acne_vulgaris.txt · Last modified: 2020/04/29 21:09 by crundle
Page Tools
